cyc 202 has been researched along with n-(2-amino-5-fluorobenzyl)-4-(n-(pyridine-3-acrylyl)aminomethyl)benzamide in 1 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (n-(2-amino-5-fluorobenzyl)-4-(n-(pyridine-3-acrylyl)aminomethyl)benzamide) | Trials (n-(2-amino-5-fluorobenzyl)-4-(n-(pyridine-3-acrylyl)aminomethyl)benzamide) | Recent Studies (post-2010) (n-(2-amino-5-fluorobenzyl)-4-(n-(pyridine-3-acrylyl)aminomethyl)benzamide) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 15 | 0 | 13 |
| Protein | Taxonomy | cyc 202 (IC50) | n-(2-amino-5-fluorobenzyl)-4-(n-(pyridine-3-acrylyl)aminomethyl)benzamide (IC50) |
|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | 0.6962 | |
| Nuclear receptor corepressor 1 | Homo sapiens (human) | 0.234 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 7.11 | |
| Histone deacetylase 4 | Homo sapiens (human) | 1.06 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.7435 | |
| Histone deacetylase 7 | Homo sapiens (human) | 1.06 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.5496 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 0.8145 | |
| Histone deacetylase 11 | Homo sapiens (human) | 1.06 | |
| Histone deacetylase 8 | Homo sapiens (human) | 1.06 | |
| Histone deacetylase 6 | Homo sapiens (human) | 4.125 | |
| Histone deacetylase 9 | Homo sapiens (human) | 1.06 | |
| Histone deacetylase 5 | Homo sapiens (human) | 1.06 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, C; Ullah, S; Yuan, Q; Yun, F | 1 |
1 other study(ies) available for cyc 202 and n-(2-amino-5-fluorobenzyl)-4-(n-(pyridine-3-acrylyl)aminomethyl)benzamide
| Article | Year |
|---|---|
Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle; Cell Line, Tumor; Colonic Neoplasms; Cyclin-Dependent Kinase 2; Drug Design; Drug Screening Assays, Antitumor; Female; Histone Deacetylases; Humans; Male; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Molecular Docking Simulation; Neoplasms, Experimental; Protein Kinase Inhibitors; Purines; Structure-Activity Relationship | 2020 |